A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
database[Title] 2025-04-21
Summary:
CONCLUSION: In light of the growing use of omadacycline in clinical practice, routinely reviewing data from the FAERS database for signals of AE can help to ensure patient medication safety and enhance overall medical quality.